Under terms of the agreement, Siemens retains non-exclusive rights to sell Calypso’s real-time tracking technology to existing and prospective Siemens linear accelerator customers throughout Europe for a period of three years.
Calypso Medical vice president of global sales Jed Palmacci said that the agreement extends the availability of the company’s GPS for the Body technology into geographic areas with significant incidences of prostate cancer.
Calypso Medical had previously entered into a master development agreement (MDA) with Siemens Healthcare to jointly develop products integrating the Calypso System with the Siemens Artiste linear accelerator and other Siemens radiotherapy technologies.
Siemens Healthcare oncology care systems chief executive officer Holger Schmidt said that the distribution agreement with Calypso Medical allows to offer customers a comprehensive, cancer treatment solution and they are pleased to represent Calypso’s technology throughout the European market.
Calypso’s GPS for the Body technology enables doctors to localize and track the tumor before and during each radiation treatment, ensuring that the tumor, not surrounding healthy tissue, receives the radiation dose.
